180 related articles for article (PubMed ID: 12181738)
1. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.
Mastroberardino PG; Iannicola C; Nardacci R; Bernassola F; De Laurenzi V; Melino G; Moreno S; Pavone F; Oliverio S; Fesus L; Piacentini M
Cell Death Differ; 2002 Sep; 9(9):873-80. PubMed ID: 12181738
[TBL] [Abstract][Full Text] [Related]
2. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
Bailey CD; Johnson GV
J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
[TBL] [Abstract][Full Text] [Related]
3. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
[TBL] [Abstract][Full Text] [Related]
4. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
Bailey CD; Johnson GV
Neurobiol Aging; 2006 Jun; 27(6):871-9. PubMed ID: 15896882
[TBL] [Abstract][Full Text] [Related]
5. Tissue transglutaminase is increased in Huntington's disease brain.
Lesort M; Chun W; Johnson GV; Ferrante RJ
J Neurochem; 1999 Nov; 73(5):2018-27. PubMed ID: 10537061
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
[TBL] [Abstract][Full Text] [Related]
7. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
Glynn D; Reim K; Brose N; Morton AJ
Brain Res Bull; 2007 Apr; 72(2-3):108-20. PubMed ID: 17352934
[TBL] [Abstract][Full Text] [Related]
8. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
Wade A; Jacobs P; Morton AJ
Brain Res; 2008 Jan; 1188():61-8. PubMed ID: 18062944
[TBL] [Abstract][Full Text] [Related]
9. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice.
Sarang Z; Molnár P; Németh T; Gomba S; Kardon T; Melino G; Cotecchia S; Fésüs L; Szondy Z
Hepatology; 2005 Sep; 42(3):578-87. PubMed ID: 16108039
[TBL] [Abstract][Full Text] [Related]
10. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease.
Menalled LB; Kudwa AE; Oakeshott S; Farrar A; Paterson N; Filippov I; Miller S; Kwan M; Olsen M; Beltran J; Torello J; Fitzpatrick J; Mushlin R; Cox K; McConnell K; Mazzella M; He D; Osborne GF; Al-Nackkash R; Bates GP; Tuunanen P; Lehtimaki K; Brunner D; Ghavami A; Ramboz S; Park L; Macdonald D; Munoz-Sanjuan I; Howland D
PLoS One; 2014; 9(6):e99520. PubMed ID: 24955833
[TBL] [Abstract][Full Text] [Related]
11. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.
Freeman W; Morton AJ
Brain Res Bull; 2004 Mar; 63(1):45-55. PubMed ID: 15121238
[TBL] [Abstract][Full Text] [Related]
12. Neurogenesis in the R6/1 transgenic mouse model of Huntington's disease: effects of environmental enrichment.
Lazic SE; Grote HE; Blakemore C; Hannan AJ; van Dellen A; Phillips W; Barker RA
Eur J Neurosci; 2006 Apr; 23(7):1829-38. PubMed ID: 16623840
[TBL] [Abstract][Full Text] [Related]
13. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.
Ribchester RR; Thomson D; Wood NI; Hinks T; Gillingwater TH; Wishart TM; Court FA; Morton AJ
Eur J Neurosci; 2004 Dec; 20(11):3092-114. PubMed ID: 15579164
[TBL] [Abstract][Full Text] [Related]
14. Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.
Prime ME; Andersen OA; Barker JJ; Brooks MA; Cheng RK; Toogood-Johnson I; Courtney SM; Brookfield FA; Yarnold CJ; Marston RW; Johnson PD; Johnsen SF; Palfrey JJ; Vaidya D; Erfan S; Ichihara O; Felicetti B; Palan S; Pedret-Dunn A; Schaertl S; Sternberger I; Ebneth A; Scheel A; Winkler D; Toledo-Sherman L; Beconi M; Macdonald D; Muñoz-Sanjuan I; Dominguez C; Wityak J
J Med Chem; 2012 Feb; 55(3):1021-46. PubMed ID: 22224594
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease.
Tallaksen-Greene SJ; Janiszewska A; Benton K; Hou G; Dick R; Brewer GJ; Albin RL
Neurosci Lett; 2009 Mar; 452(1):60-2. PubMed ID: 19429000
[TBL] [Abstract][Full Text] [Related]
16. Tissue transglutaminase overexpression does not modify the disease phenotype of the R6/2 mouse model of Huntington's disease.
Kumar A; Kneynsberg A; Tucholski J; Perry G; van Groen T; Detloff PJ; Lesort M
Exp Neurol; 2012 Sep; 237(1):78-89. PubMed ID: 22698685
[TBL] [Abstract][Full Text] [Related]
17. Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease.
Ramaswamy S; McBride JL; Herzog CD; Brandon E; Gasmi M; Bartus RT; Kordower JH
Neurobiol Dis; 2007 May; 26(2):375-84. PubMed ID: 17336076
[TBL] [Abstract][Full Text] [Related]
18. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
Bailey CD; Graham RM; Nanda N; Davies PJ; Johnson GV
Mol Cell Neurosci; 2004 Mar; 25(3):493-503. PubMed ID: 15033177
[TBL] [Abstract][Full Text] [Related]
19. Transglutaminase 2 regulates mallory body inclusion formation and injury-associated liver enlargement.
Strnad P; Harada M; Siegel M; Terkeltaub RA; Graham RM; Khosla C; Omary MB
Gastroenterology; 2007 Apr; 132(4):1515-26. PubMed ID: 17408647
[TBL] [Abstract][Full Text] [Related]
20. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease.
Papalexi E; Persson A; Björkqvist M; Petersén A; Woodman B; Bates GP; Sundler F; Mulder H; Brundin P; Popovic N
Eur J Neurosci; 2005 Sep; 22(6):1541-6. PubMed ID: 16190907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
